Key result
Inhibition of EGFR via mutation or AG1478 prevented Angiotensin II-induced hypertrophy in cerebral arterioles, but not inward remodeling, independent of blood pressure.
Why the study?
Does EGFR inhibition prevent Angiotensin II-mediated cerebrovascular remodeling and hypertrophy in mice?
Does EGFR inhibition prevent Angiotensin II-mediated cerebrovascular remodeling and hypertrophy in mice?
EGFR-dependent signaling is critical for Angiotensin II-induced hypertrophy in cerebral arterioles, independent of blood pressure changes.
Does not support clinical translation of EGFR inhibition; hypothesis-generating for selective effects on Ang II-mediated cerebrovascular changes in mice.
Angiotensin II (Ang II) is a major determinant of vascular remodeling in the cerebral circulation during chronic hypertension, which is an important risk factor for stroke. We examined the molecular mechanism of Ang II-mediated cerebrovascular remodeling that involves the epidermal growth factor receptor (EGFR) pathway. Mutant EGFR mice (waved-2), their heterozygous control (wild-type [WT]), and C57BL/6J mice were infused with Ang II (1000 ng kg(-1) min(-1)) or saline via osmotic minipumps for 28 days (n=8 per group). Eight of the Ang II-infused C57BL/6J mice were cotreated with AG1478 (12 mg/kg per day, IP), a specific EGFR tyrosine kinase inhibitor. Systolic arterial pressure was measured by a tail-cuff method. Pressure and diameter of cerebral arterioles were measured through an open cranial window in anesthetized mice. Cross-sectional area of the wall was determined in pressurized fixed cerebral arterioles. Expression of phosphorylated EGFR (p-EGFR), caveolin-1 (Cav-1), and c-Src was determined by western blotting and immunohistochemistry. Mutation of EGFR or AG1478 treatment did not affect Ang II-induced hypertension. Ang II increased the expression of p-EGFR in WT mice, confirming the activation of EGFR. Ang II induced hypertrophy and inward remodeling of cerebral arterioles in WT mice. Hypertrophy, but not remodeling, was prevented in waved-2 and AG1478-treated C57BL/6J mice. Ang II increased p-EGFR, Cav-1, and c-Src expression in WT but not in waved-2 or AG1478-treated C57BL/6J mice. These results suggest that Ang II-induced hypertrophy in cerebral arterioles involves EGFR-dependent signaling and may include Cav-1 and nonreceptor tyrosine kinase c-Src. This signaling pathway seems to be limited to Ang II-induced hypertrophy, but not inward remodeling, and is independent of blood pressure.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2015) studied Angiotensin II-induced hypertension and cerebrovascular remodeling. EGFR mutation (waved-2) or AG1478 (EGFR tyrosine kinase inhibitor) vs. Wild-type mice was evaluated on Hypertrophy and inward remodeling of cerebral arterioles. Inhibition of EGFR via mutation or AG1478 prevented Angiotensin II-induced hypertrophy in cerebral arterioles, but not inward remodeling, independent of blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: